

Cholera (Infectious Disease) - Drugs in Development, 2021

<https://marketpublishers.com/r/CC5844C8B53EEN.html>

Date: March 2021

Pages: 64

Price: US\$ 2,000.00 (Single User License)

ID: CC5844C8B53EEN

Abstracts

Cholera (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Drugs in Development, 2021, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, *Vibrio cholera*, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in

therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 1, 6 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based

on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Cholera - Overview
- Cholera - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cholera - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cholera - Companies Involved in Therapeutics Development
- Emergent BioSolutions Inc
- Global BioLife Inc Ltd
- Napo Pharmaceuticals Inc
- Ostrich Pharma USA Inc
- Vanda Pharmaceuticals Inc
- Cholera - Drug Profiles
- Antibodies for Cholera - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BPO-27 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera (whole cell) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera [strain O1/EI/Tor/Ogawa] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

cholera strain [CVD 103-HgR] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholvax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crofelemer DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gram-negative bacterial infections vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSUTMR-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholera - Dormant Projects

Cholera - Discontinued Products

Cholera - Product Development Milestones

Featured News & Press Releases

Jan 28, 2021: CHMP recommended extensions of indication for Vaxchora

Jan 31, 2020: Emergent BioSolutions receives positive CHMP opinion for Vaxchora; anticipates near-term approval by European Medicines Agency

Jun 04, 2019: Emergent BioSolutions announces FDA approval of change in storage conditions and transfer of manufacturing for its cholera vaccine

Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks

Dec 11, 2017: PaxVax: Single-dose vaccine could provide faster protection in cholera epidemics

Dec 06, 2017: Randomized Placebo-Controlled Study Provides Encouraging Results for a Higher Dose Formulation of Vaxchora (CVD 103-HgR) as a Potential Tool in Containing Cholera Epidemics

Oct 24, 2016: PaxVax's Vaxchora Now Available as the Only U.S. Approved Vaccine for Protection Against Cholera

Jun 23, 2016: CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax's Single-Dose Oral Cholera Vaccine

Jun 20, 2016: FDA Approves PaxVax to Manufacture Vaxchora (Oral Cholera Vaccine) at SynCo Bio Partners

Jun 10, 2016: FDA approves vaccine to prevent cholera for travelers

Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine

Dec 16, 2015: U.S. Food and Drug Administration Accepts Biologics License

Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora

Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix

Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cholera, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Cholera - Pipeline by Emergent BioSolutions Inc, 2021
Cholera - Pipeline by Global BioLife Inc Ltd, 2021
Cholera - Pipeline by Napo Pharmaceuticals Inc, 2021
Cholera - Pipeline by Ostrich Pharma USA Inc, 2021
Cholera - Pipeline by Vanda Pharmaceuticals Inc, 2021
Cholera - Dormant Projects, 2021
Cholera - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Cholera, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Targets, 2021
- Number of Products by Stage and Targets, 2021
- Number of Products by Mechanism of Actions, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Cholera (Infectious Disease) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/CC5844C8B53EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC5844C8B53EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970